US FDA approves Mesoblast's cell therapy for graft-versus-host disease

Mesoblast

18/12/2024 21:50

Dec 18 (Reuters) - The U.S. Food and Drug Administration
on Wednesday approved Mesoblast's  MSB.AX  cell therapy for
treating a type of complication that occurs after a stem cell or
bone marrow transplant called graft-versus-host disease.

 (Reporting by Sriparna Roy in Bengaluru; Editing by Vijay
Kishore)
 ((Sriparna.Roy@thomsonreuters.com;))